Author: Shannon, Vickie R.; Anderson, Ronald; Blidner, Ada; Choi, Jennifer; Cooksley, Tim; Dougan, Michael; Glezerman, Ilya; Ginex, Pamela; Girotra, Monica; Gupta, Dipti; Johnson, Douglas B.; Suarez-Almazor, Maria E.; Rapoport, Bernardo L.
Title: Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity Cord-id: y3vejwtr Document date: 2020_9_3
ID: y3vejwtr
Snippet: The immune checkpoints associated with the CTLA-4 and PD-1 pathways are critical modulators of immune activation. These pathways dampen the immune response by providing brakes on activated T cells, thereby ensuring more uniform and controlled immune reactions and avoiding immune hyper-responsiveness and autoimmunity. Cancer cells often exploit these regulatory controls through a variety of immune subversion mechanisms, which facilitate immune escape and tumor survival. Immune checkpoint inhibito
Document: The immune checkpoints associated with the CTLA-4 and PD-1 pathways are critical modulators of immune activation. These pathways dampen the immune response by providing brakes on activated T cells, thereby ensuring more uniform and controlled immune reactions and avoiding immune hyper-responsiveness and autoimmunity. Cancer cells often exploit these regulatory controls through a variety of immune subversion mechanisms, which facilitate immune escape and tumor survival. Immune checkpoint inhibitors (ICI) effectively block negative regulatory signals, thereby augmenting immune attack and tumor killing. This process is a double-edged sword in which release of regulatory controls is felt to be responsible for both the therapeutic efficacy of ICI therapy and the driver of immune-related adverse events (IrAEs). These adverse immune reactions are common, typically low-grade and may affect virtually every organ system. In the early clinical trials, lung IrAEs were rarely described. However, with ever-expanding clinical applications and more complex ICI-containing regimens, lung events, in particular, pneumonitis, have become increasingly recognized. ICI-related lung injury is clinically distinct from other types of lung toxicity and may lead to death in advanced stage disease. Thus, knowledge regarding the key characteristics and optimal treatment of lung-IrAEs is critical to good outcomes. This review provides an overview of lung-IrAEs, including risk factors and epidemiology, as well as clinical, radiologic, and histopathologic features of ICI-related lung injury. Management principles for ICI-related lung injury, including current consensus on steroid refractory pneumonitis and the use of other immune modulating agents in this setting are also highlighted.
Search related documents:
Co phrase search for related documents- acute ards respiratory distress syndrome and adaptive immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- acute ards respiratory distress syndrome and additional information: 1, 2, 3
- acute ards respiratory distress syndrome and additional information offer: 1
- acute ards respiratory distress syndrome and additional study: 1, 2, 3, 4, 5
- acute ards respiratory distress syndrome and admission chest ct: 1, 2, 3
- acute ards respiratory distress syndrome and low grade fever: 1, 2, 3
- acute ards respiratory distress syndrome and lung biopsy: 1, 2, 3, 4, 5, 6, 7, 8
- acute ards respiratory distress syndrome and lung cancer: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
- acute ards respiratory distress syndrome and lung cancer patient: 1
- adaptive immune response and low grade fever: 1
- adaptive immune response and lung cancer: 1
- additional information and lung cancer: 1, 2
- additional study and admission chest ct: 1
- additional study and lung cancer: 1, 2
- admission chest ct and lung biopsy: 1, 2, 3, 4
- low grade fever and lung cancer: 1, 2
Co phrase search for related documents, hyperlinks ordered by date